Literature DB >> 17514361

Arterial thrombosis and thalidomide.

Mustafa Goz1, M Nesimi Eren, Omer Cakir.   

Abstract

Arterial emboli are largely a reflection of cardiac disease. Thalidomide is an antiangiogenic drug used in cancer therapy. Venous thrombosis incidence increased during treatment with thalidomide. We reported arterial thrombosis in two cases with multiple myeloma implemented in thalidomide treatment. Standard emergency intervention was applied. In the postoperative period, enoxiparine was given to all the patients. Warfarin treatment was started in the level of INR 2-2,5. ASA with a dose of 100 mg/day was added to the treatment. In conclusion, this side effect of the use of thalidomide should be taken into consideration while doing examinations with respect to the etiology in arterial thromboembolism and because of this vascular complication that threatens life; we suggest stopping the thalidomide treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17514361     DOI: 10.1007/s11239-007-0057-1

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  12 in total

Review 1.  Thalidomide-associated deep vein thrombosis and pulmonary embolism.

Authors:  Charles L Bennett; Glen T Schumock; Apurva A Desai; Hau C Kwaan; Dennis W Raisch; Rebecca Newlin; Walter Stadler
Journal:  Am J Med       Date:  2002-11       Impact factor: 4.965

2.  Venous sinus thrombosis in a patient taking thalidomide.

Authors:  Robert A Lenz; Jeffrey Saver
Journal:  Cerebrovasc Dis       Date:  2004-07-13       Impact factor: 2.762

3.  Thalidomide, deep venous thrombosis and vasculitis.

Authors:  M Silingardi; M Iotti; C Trenti; C Salvarani; I Iori
Journal:  J Thromb Haemost       Date:  2004-11       Impact factor: 5.824

4.  Thalidomide in front line treatment in multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis.

Authors:  C Rus; M Bazzan; A Palumbo; S Bringhen; M Boccadoro
Journal:  J Thromb Haemost       Date:  2004-11       Impact factor: 5.824

5.  Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.

Authors:  P Schütt; P Ebeling; U Buttkereit; D Brandhorst; B Opalka; M Hoiczyk; M Flasshove; J Hense; P Bojko; K Metz; T Moritz; S Seeber; M R Nowrousian
Journal:  Eur J Haematol       Date:  2005-01       Impact factor: 2.997

6.  Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

Authors:  M Zangari; E Anaissie; B Barlogie; A Badros; R Desikan; A V Gopal; C Morris; A Toor; E Siegel; L Fink; G Tricot
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

7.  Thromboembolism in patients on thalidomide for myeloma.

Authors:  Stella J Bowcock; Saad M B Rassam; Sue M Ward; Jacky T Turner; Mike Laffan
Journal:  Hematology       Date:  2002-02       Impact factor: 2.269

Review 8.  Thalidomide for the treatment of multiple myeloma.

Authors:  Yutaka Hattori; Toyotaka Iguchi
Journal:  Congenit Anom (Kyoto)       Date:  2004-09       Impact factor: 1.409

Review 9.  [Left atrial thrombus in multiple myeloma treated with thalidomide].

Authors:  C Jégo; F Barbou; P Laurent; O Gisserot; G Cellarier; J Bonal; C Bouchiat; C Landais; J P de Jaureguiberry; G V Dussarat
Journal:  Arch Mal Coeur Vaiss       Date:  2003-10

10.  Thalidomide is an inhibitor of angiogenesis.

Authors:  R J D'Amato; M S Loughnan; E Flynn; J Folkman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

View more
  6 in total

1.  Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study.

Authors:  Sigurdur Y Kristinsson; Ruth M Pfeiffer; Magnus Björkholm; Lynn R Goldin; Sam Schulman; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2010-03-18       Impact factor: 22.113

2.  High rates of venous and arterial thrombotic events in patients with POEMS syndrome: results from the UCLH (UK) POEMS Registry.

Authors:  Zara Sayar; Anna Weatherill; Stephen Keddie; Jonathan Sive; Michael P Lunn; Mari Thomas; Shirley D'Sa
Journal:  Blood Adv       Date:  2020-05-26

Review 3.  Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention.

Authors:  Dae Hyun Lee; Michael G Fradley
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-03-06

4.  Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.

Authors:  Martin Hjorth; Øyvind Hjertner; Lene Meldgaard Knudsen; Nina Gulbrandsen; Erik Holmberg; Per Trøllund Pedersen; Niels Frost Andersen; Björn Andréasson; Rolf Billström; Kristina Carlson; Margaretha S Carlsson; Max Flogegård; Karin Forsberg; Peter Gimsing; Torbjörn Karlsson; Olle Linder; Hareth Nahi; Annika Othzén; Agneta Swedin
Journal:  Eur J Haematol       Date:  2012-03-30       Impact factor: 2.997

5.  A Case of Internal Carotid Artery Thrombosis associated with Thalidomide Administration in Multiple Myeloma.

Authors:  Maria Angela Grima; David James Camilleri
Journal:  Eur J Case Rep Intern Med       Date:  2016-05-04

6.  Multifocal Arterial Thrombosis during Thalidomide Therapy: Case Report and Review of the Literature.

Authors:  Monica Ferri; Gianluca Faggioli; Francesca Fratesi; Andrea Stella
Journal:  Case Rep Med       Date:  2009-08-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.